Report cover image

Global Next-Generation Antibody Therapeutics Market

Publisher Fatpos Global
Published Jul 01, 2022
Length 90 Pages
SKU # FAGL17509541

Description

Global Next-Generation Antibody Therapeutics Market

Use of a new improvised therapeutic antibody to form novel medicines for the treatment of different

diseases includes next-generation antibody therapeutics. Next-generation antibody therapeutics have been

clinically developed for many diseases by pharmaceutical and biotechnology firms. Next-generation

antibody-based therapeutics for the treatment of different medical conditions such as cancer, infectious

diseases, and autoimmune diseases improve the current properties of therapeutic antibodies. For the

reason of their unique pharmacological characteristics, the science and development involved in the

production of next-generation antibodies generate great interest for many biotech and pharmaceutical

companies, increase specificity for established cell types, and low intrinsic toxicity. Sacituzumab govitecan,

an antibody-drug conjugate (ADC) composed of a humanized anti-Trop-2 antibody conjugated to SN38 is

studied for the treatment of patients with metastatic triple-negative breast cancer. Immunomedics, a

pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of

cancer is planning clinical studies of the ADC in other cancers.

Market Size
  • 2019: USD 4,747.22 Million
  • 2025: USD 11,924.25 Million
  • 2030: USD 29,825.60 Million
CAGR (2020– 2030)
  • 18.5%
Key Geographies

  • North America
    • Key Therapeutic Areas
    • Oncology
    • Autoimmune/Inflammatory
    Key Technology
    • Antibody-Drug Conjugates (ADCs)
    • Bispecific Antibodies
    Key Market Drivers
    • Increasing investments in healthcare infrastructural development
    • Increasing volume of chronic patients
    Key Market Opportunities
    • Development of antibody therapeutics for other diseases
    Major Players/Companies
    • Bristol-Myers Squibb
    • Pfizer
    • Roche

    Table of Contents

    90 Pages
    1. Executive Summary
    1.1 Regional Market Share
    1.2 Next-Generation Antibody Therapeutics Market: COVID-19 Outbreak
    2. Research Methodology
    2.1 Research Objective
    2.2 Research Approach
    2.3 Data Sourcing and Methodology
    2.4 Primary Research
    2.5 Secondary Research
    2.6 Market Size Estimation and Data Triangulation
    3. Market Characteristics
    3.1 Market Definition
    3.2 Key Segmentations
    3.3 Key Developments
    3.4 Allied Industry Data: Healthcare Industry
    4. Recent Developments
    4.1 Overview
    4.2 Product Launch
    4.3 Major Management Change
    4.4 Mergers & Acquisitions Activities
    4.5 Latest Technological Advancements
    5. Export-Import Analysis
    5.1 Monoclonal Antibody EXIM Data Analysis
    5.2 Major EXIM Statistics
    5.3 Antibody EXIM data for the key countries
    5.3.1 United States
    5.3.2 China
    5.3.3 India
    5.3.4 Germany
    5.3.5 Spain
    6. Market Dynamics
    6.1 Introduction
    6.2 Growth Drivers
    6.2.1 Increasing investments in healthcare infrastructural development
    6.2.2 Increasing volume of chronic patients
    6.2.3 Government initiatives
    6.3 Restraints
    6.3.1 Stringent rules & regulations
    6.3.2 High cost involved in research and development for developing next-generation antibodies
    6.4 Opportunities
    6.4.1 Development of antibody therapeutics for other diseases
    6.4.2 Mergers and acquisitions by major market players
    6.5 Trends
    6.5.1 Advancements in technology
    6.5.2 Rising demand for ADC technology
    7. Market Analysis
    7.1 Porters Five Forces
    7.1.1 Threat of New Entrants
    7.1.2 Bargaining Power of Customer
    7.1.3 Bargaining Power of Suppliers
    7.1.4 Threat of Substitutes
    7.1.5 Competitive rivalry
    7.2 PEST Analysis
    7.2.1 Political
    7.2.2 Economic
    7.2.3 Social
    7.2.4 Technological
    8. Market Size & Forecast 2019A-2030F
    8.1 Global Next-Generation Antibody Therapeutics Market: Overview
    8.2 Global Conventional Antibody Therapeutics Market: Overview
    8.3 Regional Market Share
    8.4 Recent Developments (3 years)
    9. Market Segmentation by Region
    9.1 North America
    9.1.1 North America Next-Generation Antibody Therapeutics Market
    9.1.2 North America Conventional Antibody Therapeutics Market
    9.2 Europe
    9.2.1 Europe Next-Generation Antibody Therapeutic Market
    9.2.2 Europe Conventional Antibody Therapeutic Market
    9.3 Asia-Pacific
    9.3.1 Asia-Pacific Next-Generation Antibody Therapeutics Market
    9.3.2 Asia-Pacific Conventional Antibody Therapeutics Market
    9.4 Latin America
    9.4.1 Latin America Next-Generation Antibody Therapeutics Market
    9.4.2 Latin America Conventional Antibody Therapeutics Market
    9.5 Middle-East & Africa
    9.5.1 Middle-East & Africa Next-Generation Antibody Therapeutics Market
    9.5.2 Middle-East & Africa Conventional Antibody Therapeutics Market
    10. Market Snippet
    10.1 Overview
    10.2 Global Next-Generation Antibody Therapeutics Market: By Technology
    10.2.1 By Technology: Antibody-Drug Conjugates (ADCs)
    10.2.2 By Technology: Bispecific Antibodies
    10.2.3 By Technology: Fc-engineered Antibodies
    10.2.4 By Technology: Antibody Fragments
    10.2.5 By Technology: Antibody-like Proteins
    10.2.6 By Technology: Biosimilar Antibody Products
    10.2.7 Market Share, By Technology (2019 –2030)
    10.3 Global Next-Generation Antibody Therapeutics Market: By Therapeutic Areas
    10.3.1 By Therapeutics Area: Oncology
    10.3.2 By Therapeutics Area: Autoimmune /inflammatory
    10.3.3 Market Share, By Therapeutics Area (2019 –2030)
    10.4 Global Conventional Antibody Therapeutics Market: By Therapeutic Areas
    10.4.1 By Therapeutics Area: Oncology
    10.4.2 By Therapeutics Area: Autoimmune /inflammatory
    10.4.3 Market Share, By Therapeutics Area (2019 –2030)
    10.5 Key Insights and Recent Developments
    11. Competitive Landscape
    11.1 Overview
    11.2 Market Share Analysis
    12. Company Profiles
    12.1 Amgen, Inc.
    12.1.1 Company Overview
    12.1.2 Key Products
    12.1.3 Financial Overview, 2015-2019 (USD Billion)
    12.1.4 Total Revenue (%) - By Segments, 2019
    12.1.6 Total Revenue (%) - By Region, 2019
    12.1.5 Key Performance Indicators
    12.1.7 Recent News & Development (last 3 yrs.)
    12.1.8 Executive Team
    12.2 AstraZenecan, Inc.
    12.2.1 Company Overview
    12.2.2 Key Products
    12.2.3 Financial Overview, 2015-2019 (USD Billion)
    12.2.4 Total Revenue (%) - By Segments, 2019
    12.2.5 Key Performance Indicators
    12.2.6 Total Revenue (%) - By Region, 2019
    12.2.7 Recent News & Development (last 3 yrs.)
    12.2.8 Executive Team
    12.3 Bayer AG
    12.3.1 Company Overview
    12.3.2 Key Products
    12.3.3 Financial Overview, 2015-2019 (USD Billion)
    12.3.4 Total Revenue (%) - By Segments, 2019
    12.3.5 Key Performance Indicators
    12.3.6 Total Revenue (%) - By Region, 2019
    12.3.7 Recent News & Development (last 3 yrs)
    12.3.8 Executive Team
    12.4 Biogen Inc
    12.4.1 Company Overview
    12.4.2 Key Products
    12.4.3 Financial Overview, 2015-2019 (USD Billion)
    12.4.4 Total Revenue (%) - By Segments, 2019
    12.4.5 Key Performance Indicators
    12.4.6 Total Revenue (%) - By Region, 2019
    12.4.7 Recent News & Development (last 3 yrs.)
    12.4.8 Executive Team
    12.5 Bristol Myers Squibb
    12.5.1 Company Overview
    12.5.2 Key Products
    12.5.3 Financial Overview, 2015-2019 (USD Billion)
    12.5.4 Total Revenue (%) - By Segment, 2019
    12.5.5 Key Performance Indicators
    12.5.6 Total Revenue (%) – By Region, 2019
    12.5.7 Recent News & Development (last 3 yrs.)
    12.5.8 Executive Team
    12.6 Immunogen Inc
    12.6.1 Company Overview
    12.6.2 Key Products
    12.6.3 Financial Overview, 2015-2019 (USD Million)
    12.6.4 Total Revenue (%) - By Operations,
    12.6.5 Key Performance Indicator
    12.6.6 Total Revenue (%) - By Collaborative Partner Segment 2019
    12.6.7 Recent News & Development (last 3 yrs.)
    12.6.8 Executive Team
    12.7 Pfizer Inc.
    12.7.1 Company Overview
    12.7.2 Key Products
    12.7.3 Financial Overview, 2015-2019 (USD Billion)
    12.7.4 Total Revenue (%) - By Segments, 2019
    12.7.5 Key Performance Indicators
    12.7.6 Total Revenue (%) - By Region, 2019
    12.7.7 Recent News & Development (last 3 yrs.)
    12.7.8 Executive Team
    12.8 Roche Holding AG
    12.8.1 Company Overview
    12.8.2 Key Products
    12.8.3 Financial Overview, 2015-2019 (USD Billion)
    12.8.4 Total Revenue (%) - By Segments, 2019
    12.8.5 Key Performance Indicators
    12.8.6 Total Revenue (%) - By Region, 2019
    12.8.7 Recent News & Development (last 3 yrs.)
    12.8.8 Executive Team
    12.9 Seattle Genetics, Inc
    12.9.1 Company Overview
    12.9.2 Key Products
    12.9.3 Financial Overview, 2015-2019 (USD Billion)
    12.9.4 Total Revenue (%) - By Segments, 2019
    12.9.5 Key Performance Indicators
    12.9.6 Total Revenue (%) - By Region, 2019
    12.9.7 Recent News & Development (last 3 yrs.)
    12.9.8 Executive Team
    12.10 Xencor
    12.10.1 Company Overview
    12.10.2 Key Products
    12.10.3 Financial Overview, 2015-2019 (USD Billion)
    12.10.4 Total Revenue (%) - By Segment, 2019
    12.10.5 Key Performance Indicator
    12.10.6 Total Revenue (%) – By Region, 2019
    12.10.7 Recent News & Development (last 3 yrs.)
    12.10.8 Executive Team
    12.11 Kyowa Hakko Kirin
    12.11.1 Company Overview
    12.11.2 Key Products
    12.11.3 Financial Overview, 2015-2019 (USD Billion)
    12.11.4 Total Revenue (%) - By Segment, 2019
    12.11.5 Key Performance Indicator
    12.11.6 Total Revenue (%) - By Region, 2019
    12.11.7 Recent News & Development (last 3 yrs.)
    12.11.8 Executive Team
    12.12 Takeda Pharmaceutical Co Ltd
    12.12.1 Company Overview
    12.12.2 Key Products
    12.12.3 Financial Overview, 2016-2020 (USD Billion)
    12.12.4 Total Revenue (%) - By Segments, 2019
    12.12.5 Key Performance Indicators
    12.12.6 Total Revenue (%) - By Region, 2019
    12.12.7 Recent News & Development (last 3 yrs.)
    12.12.8 Executive Team
    12.13 AbbVie
    12.13.1 Company Overview
    12.13.2 Key Products
    12.13.4 Total Revenue (%) - By Segment, 2019
    12.13.3 Financial Overview, 2015-2019 (USD Billion)
    12.13.5 Key Performance Indicator
    12.13.6 Total Revenue (%) - By Region, 2019
    12.13.7 Recent News & Development (last 3 yrs.)
    12.13.8 Executive Team
    12.14 Johnson & Johnson
    12.14.1 Company Overview
    12.14.2 Key Products
    12.14.3 Financial Overview, 2015-2019 (USD Billion)
    12.14.4 Total Revenue (%) - By Segments, 2019
    12.14.5 Key Performance Indicator
    12.14.6 Total Revenue (%) - By Region, 2019
    12.14.7 Recent News & Development (last 3 yrs.)
    12.14.8 Executive Team
    12.15 Novartis AG
    12.15.1 Company Overview
    12.15.2 Key Products
    12.15.3 Financial Overview, 2015-2019 (USD Billion)
    12.15.4 Total Revenue (%) - By Segment, 2019
    12.15.5 Key Performance Indicator
    12.15.6 Total Revenue (%) - By Region, 2019
    12.15.7 Recent News & Development (last 3 yrs.)
    12.15.8 Executive Team
    13. Appendix
    13.1 List of Abbreviations

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us